Literature DB >> 22103564

Survival and regeneration of deep-freeze preserved autologous cranial bones after cranioplasty.

Yi Lu1, Guozhen Hui, Fengqiang Liu, Zhengan Wang, Yuming Tang, Shuxing Gao.   

Abstract

BACKGROUND: After decompressive craniectomy, a deep-freeze-preserved autologous cranial bone graft can be used for cranioplasty to avoid immunoreaction against an artificial patch material. Autologous cranial bone grafts not only have better physical properties, such as heat conduction, compared to artificial patch materials, but they also have the advantages of a lower medical cost and satisfactory physical flexibility. The discussion over (99)Tc(m)-MDP SPECT static cranial bone tomography in the diagnosis of survival and regeneration in deep-freeze preservation autologous cranial bones after cranioplasty is valuable. Objective. To investigate whether deep-freeze-preserved autologous cranial bone grafts could survive and regenerate after autologous reimplantation.
METHODS: The method of cranial bone preservation involved removing the cranial graft and sealing it in a double-layer sterile plastic bag under sterile surgical conditions. On the day of the cranioplasty operation, the cranial bone graft was disinfected by immersing it in 3% povidone-iodine for 30 minutes. At short-term (2 weeks), medium-term (3 months), and long-term (12 months) postoperative follow-up visits, (99)Tc(m)-MDP SPECT static cranial bone tomography was used to examine the reimplanted cranial bone. Results. There were no postoperative infections or seromas in all 16 cases. Two weeks following cranial bone graft reimplantation, the SPECT tomography showed some radioactivity uptake in the reimplanted cranial bone graft, which was lower than that in the cranial bone on the healthy side. At 3 months and 12 months after the operation, the radioactivity uptake in the reimplanted cranial bone graft was the same as that in the cranial bone on the healthy side. X-ray films showed blurred sutures in the reimplanted cranial bone graft at 12 months after surgery.
CONCLUSION: Reimplanted deep-freeze-preserved autologous cranial bone can survive in the short term and regenerate in the medium and long terms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22103564     DOI: 10.3109/02688697.2011.629699

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  6 in total

Review 1.  The storage of skull bone flaps for autologous cranioplasty: literature review.

Authors:  Vicente Mirabet; Daniel García; Nuria Yagüe; Luis Roberto Larrea; Cristina Arbona; Carlos Botella
Journal:  Cell Tissue Bank       Date:  2021-01-09       Impact factor: 1.522

2.  A Retrospective Study of Complications in Cranioplasty: 7-Year Period.

Authors:  S K Roy Chowdhury; Ashok Kumar; Prashant Kumar
Journal:  J Maxillofac Oral Surg       Date:  2020-11-23

3.  Delayed Cranioplasty: Outcomes Using Frozen Autologous Bone Flaps.

Authors:  Daniel Hng; Ivan Bhaskar; Mumtaz Khan; Charley Budgeon; Omprakash Damodaran; Neville Knuckey; Gabriel Lee
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2014-12-17

4.  Analysis of the Risk Factors Affecting the Surgical Site Infection after Cranioplasty Following Decompressive Craniectomy.

Authors:  Jin Seong Kim; In Sung Park; Sung Kwon Kim; Hyun Park; Dong-Ho Kang; Chul-Hee Lee; Soo-Hyun Hwang; Jin-Myung Jung; Jong-Woo Han
Journal:  Korean J Neurotrauma       Date:  2015-10-31

5.  A Multicentric European Clinical Study on Custom-Made Porous Hydroxyapatite Cranioplasty in a Pediatric Population.

Authors:  Ismail Zaed; Adrian Safa; Piero Spennato; Carmine Mottolese; Salvatore Chibbaro; Delia Cannizzaro; Roberto Faggin; Paolo Frassanito; Rodolfo Maduri; Mahmoud Messerer; Franco Servadei
Journal:  Front Surg       Date:  2022-03-23

6.  Cranioplasty with autologous cryopreserved bone after decompressive craniectomy: complications and risk factors for developing surgical site infection.

Authors:  J Sundseth; A Sundseth; J Berg-Johnsen; W Sorteberg; K-F Lindegaard
Journal:  Acta Neurochir (Wien)       Date:  2014-02-04       Impact factor: 2.216

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.